Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC, 70147 [2021-26678]
Download as PDF
<![CDATA[
70147
Federal Register / Vol. 86, No. 234 / Thursday, December 9, 2021 / Notices
submissions will be available for public
inspection on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and in Part 210 of the Commission’s
Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: December 3, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–26626 Filed 12–8–21; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 701–TA–665 (Final)]
Certain Mobile Access Equipment and
Subassemblies Thereof From China;
Determination
On the basis of the record 1 developed
in the subject investigation, the United
States International Trade Commission
(‘‘Commission’’) determines, pursuant
to the Tariff Act of 1930 (‘‘the Act’’),
that an industry in the United States is
threatened with material injury by
reason of imports of certain mobile
access equipment and subassemblies
thereof (‘‘mobile access equipment’’)
from China, provided for in subheadings
8427.10.80, 8427.20.80, 8427.90.00, and
8431.20.00 of the Harmonized Tariff
Schedule of the United States, that have
been found by the U.S. Department of
Commerce (‘‘Commerce’’) to be
subsidized by the government of China.2
khammond on DSKJM1Z7X2PROD with NOTICES
Background
The Commission instituted this
investigation effective February 26,
2021, following receipt of a petition
filed with the Commission and
Commerce by the Coalition of American
Manufacturers of Mobile Access
Equipment (‘‘CAMMAE’’ or ‘‘the
Coalition’’).3 The Commission
scheduled the final phase of the
investigation following notification of a
preliminary determination by
Commerce that imports of mobile access
equipment from China were being
subsidized within the meaning of
section 703(b) of the Act (19 U.S.C.
1671b(b)). Notice of the scheduling of
the final phase of the Commission’s
investigation and of a public hearing to
1 The record is defined in § 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR 207.2(f)).
2 86 FR 57809 (October 19, 2021).
3 The Coalition is composed of JLG Industries,
Inc. (‘‘JLG’’), Hagerstown, Maryland and Terex
Corporation (‘‘Terex’’), Redmond, Washington.
VerDate Sep<11>2014
17:41 Dec 08, 2021
Jkt 256001
be held in connection therewith was
given by posting copies of the notice in
the Office of the Secretary, U.S.
International Trade Commission,
Washington, DC, and by publishing the
notice in the Federal Register of August
12, 2021 (86 FR 44402). In light of the
restrictions on access to the Commission
building due to the COVID–19
pandemic, the Commission conducted
its hearing through written testimony
and video conference on October 12,
2021. All persons who requested the
opportunity were permitted to
participate.
The Commission made this
determination pursuant to § 705(b) of
the Act (19 U.S.C. 1671d(b)). It
completed and filed its determination in
this investigation on December 3, 2021.
The views of the Commission are
contained in USITC Publication 5242
(December 2021), entitled Certain
Mobile Access Equipment and
Subassemblies Thereof from China:
Investigation No. 701–TA–665 (Final).
By order of the Commission.
Issued: December 3, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–26623 Filed 12–8–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–938]
Importer of Controlled Substances
Application: Catalent Pharma
Solutions, LLC
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on September 10, 2021,
Catalent Pharma Solutions LLC, 3031
Red Lion Road, Philadelphia,
Pennsylvania 19114, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
Drug
code
Controlled substance
Psilocybin ......................
Psilocyn .........................
I
7437
7438
Schedule
I
I
I
The company plans to import the
above controlled substances as finished
dosage unit products for clinical trials,
research, and analytical activities. No
other activity for these drug codes is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
[FR Doc. 2021–26678 Filed 12–8–21; 8:45 am]
BILLING CODE P
Catalent Pharma Solutions,
LLC has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 10, 2022. Such
persons may also file a written request
for a hearing on the application on or
before January 10, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA 937]
Importer of Controlled Substances
Application: Fresenius Kabi USA, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Fresenius Kabi USA, LLC has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
SUMMARY:
E:\FR\FM\09DEN1.SGM
09DEN1
]]>Agencies
[Federal Register Volume 86, Number 234 (Thursday, December 9, 2021)]
[Notices]
[Page 70147]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26678]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-938]
Importer of Controlled Substances Application: Catalent Pharma
Solutions, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Catalent Pharma Solutions, LLC has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before January 10,
2022. Such persons may also file a written request for a hearing on the
application on or before January 10, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on September 10, 2021, Catalent Pharma Solutions LLC,
3031 Red Lion Road, Philadelphia, Pennsylvania 19114, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Psilocybin............................. 7437 I
Psilocyn............................... 7438 I
------------------------------------------------------------------------
The company plans to import the above controlled substances as
finished dosage unit products for clinical trials, research, and
analytical activities. No other activity for these drug codes is
authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021-26678 Filed 12-8-21; 8:45 am]
BILLING CODE P
